What is the 13F Pro Quality Score for INSP?

13F Pro ranks Inspire Medical Systems, Inc. (INSP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INSP's current score at https://13fpro.ai/research/INSP (free sign-up required for the full ranking).

Where does 13F Pro source INSP data?

All Inspire Medical Systems, Inc. fundamentals and ownership data come directly from SEC EDGAR. Inspire Medical Systems, Inc. files with the SEC under CIK 1609550. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INSP in?

Inspire Medical Systems, Inc. (INSP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INSP research updated on 13F Pro?

INSP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Inspire Medical Systems, Inc.(INSP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1609550 INSP stock profile & AI dashboard →

13F Pro Quality Score

46.0/100

Rank #1,693 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

80.2/100

Profitability

30.3/100

Balance Sheet

34.9/100

Earnings Quality

30.0/100

Free Cash Flow

49.7/100

Institutional Flow

42.2/100

Revenue Scale

46.4/100

Dilution Risk

12.9/100

INSP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Inspire Medical Systems, Inc. (INSP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INSP at 46.0/100 on a 32-signal composite quality model, placing it at rank #1,693 of 2,879 stocks — the bottom half of the AI-ranked universe. INSP scores in the top quartile across revenue growth (80.2). Areas of concern include earnings quality (30.0) and profitability (30.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Inspire Medical Systems, Inc. reports quarterly revenue of $204.6M, net income of $-11.3M, free cash flow of $3.1M. Top institutional holders of INSP by reported 13-F value include BlackRock,, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. INSP trades on the NYSE exchange and files with the SEC under CIK 1609550. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inspire Medical Systems, Inc. directly from SEC EDGAR. Inspire Medical Systems, Inc.'s 13F Pro composite quality score has ranged between 29 and 61 since 2021, currently 46.0 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

Revenue

Q1 2026

$204.6M

Net Income

Q1 2026

$-11.3M

Free Cash Flow

Q1 2026

$3.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+123.6% YoY

$912.0MFY 2025

FY20 $115.4MFY21 $233.4MFY22 $407.9MFY25 $912.0M

Net Income

+424.0% YoY

$145.4MFY 2025

FY20 $-57.2MFY21 $-42.0MFY22 $-44.9MFY25 $145.4M

Operating Income

+207.1% YoY

$51.0MFY 2025

FY20 $-56.2MFY21 $-39.9MFY22 $-47.6MFY25 $51.0M

EPS (Diluted)

+405.6% YoY

$4.89FY 2025

FY20 $-2.19FY21 $-1.54FY22 $-1.60FY25 $4.89

Total Assets

+60.6% YoY

$907.3MFY 2025

FY20 $281.2MFY21 $295.1MFY22 $564.9MFY25 $907.3M

Total Debt

—FY 2025

FY20 $24.5MFY21 $24.5MFY22 —FY25 —

Op. Cash Flow

+911.1% YoY

$117.0MFY 2025

FY20 $-53.0MFY21 $-20.1MFY22 $11.6MFY25 $117.0M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$912.0M +123.6%	$407.9M +74.7%	$233.4M +102.3%	$115.4M +40.6%	$82.0M +62.2%	$50.6M
Net Income	$145.4M +424.0%	$-44.9M -6.8%	$-42.0M +26.5%	$-57.2M -72.1%	$-33.2M -52.3%	$-21.8M
Operating Income	$51.0M +207.1%	$-47.6M -19.4%	$-39.9M +29.1%	$-56.2M -61.1%	$-34.9M -71.2%	$-20.4M
EPS (Diluted)	$4.89 +405.6%	$-1.60 -3.9%	$-1.54 +29.7%	$-2.19 -56.4%	$-1.40	—
Total Assets	$907.3M +60.6%	$564.9M +91.4%	$295.1M +4.9%	$281.2M +55.1%	$181.3M -9.4%	$200.1M
Total Debt	—	—	$24.5M +0.0%	$24.5M +0.0%	$24.5M +0.0%	$24.5M
Operating Cash Flow	$117.0M +911.1%	$11.6M +157.5%	$-20.1M +62.1%	$-53.0M -61.5%	$-32.8M -75.7%	$-18.7M

AI Insight: INSP Financial Trends

INSP shows strong Q4 seasonality but faces concerning sequential declines in Q1 with negative net income of -$11M.

• Revenue demonstrates clear seasonality with Q4 peaks at $240M (2024) and $269M (2025), but Q1 consistently weak at $201M and $205M.

• Net income swung dramatically from $136M in Q4 2025 to -$11M in Q1 2026, the worst quarterly loss in the dataset.

• Operating income turned negative in Q1 2026 at -$1M after strong Q4 2025 performance of $46M.

⚠ Q1 2026 marks the second time operating income went negative, suggesting potential structural profitability challenges beyond seasonality.

⚠ Operating cash flow volatility remains high, swinging from $52M in Q4 2025 to $13M in Q1 2026.

AI Insight: INSP Ratio Trends

INSP exhibits extreme quarterly volatility with operating margins swinging from 17.1% in Q4 2025 to -0.5% in Q1 2026.

• Operating margin collapsed from 17.1% in Q4 2025 to -0.5% in Q1 2026, showing severe seasonal pattern.

• Net profit margin plunged from 50.6% in Q4 2025 to -5.5% in Q1 2026, indicating dramatic quarterly swings.

• ROIC deteriorated from 23.6% in Q4 2025 to -0.6% in Q1 2026, reflecting poor capital efficiency in Q1.

⚠ Consistent Q1 underperformance across all profitability metrics suggests significant seasonal headwinds or operational challenges.

⚠ Q4 spikes in margins appear unsustainable given immediate Q1 reversals in both 2025 and 2026.

Get alerted when INSP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inspire Medical Systems, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INSP

BlackRock, Inc.
$183.1M3,549,554 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$139.4M2,703,238 sh
WELLINGTON MANAGEMENT GROUP LLP
$130.8M2,535,954 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$84.4M1,637,173 sh
MORGAN STANLEY
$74.8M1,450,634 sh
VANGUARD CAPITAL MANAGEMENT LLC
$65.3M1,266,738 sh
D. E. Shaw & Co., Inc.
$61.3M1,188,537 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$58.7M1,137,384 sh
STATE STREET CORP
$49.3M956,011 sh
Artisan Partners Limited Partnership
$40.3M780,575 sh

Fund	Value	Shares
BlackRock, Inc.	$183.1M	3,549,554
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$139.4M	2,703,238
WELLINGTON MANAGEMENT GROUP LLP	$130.8M	2,535,954
VANGUARD PORTFOLIO MANAGEMENT LLC	$84.4M	1,637,173
MORGAN STANLEY	$74.8M	1,450,634
VANGUARD CAPITAL MANAGEMENT LLC	$65.3M	1,266,738
D. E. Shaw & Co., Inc.	$61.3M	1,188,537
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$58.7M	1,137,384
STATE STREET CORP	$49.3M	956,011
Artisan Partners Limited Partnership	$40.3M	780,575

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INSP on your watchlist

Track score changes the day Inspire Medical Systems, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INSP a good stock to buy?

13F Pro's AI-powered analysis of Inspire Medical Systems, Inc. (INSP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INSP are available on the INSP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INSP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INSP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inspire Medical Systems, Inc.'s investment landscape.